Terbinafine

🧮 Dose calculator

Onychomycosis · Regimen source: FDA Terbinafine · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Terbinafine · 8.1

  “​ Risk Summary Available data from postmarketing cases on the use of terbinafine tablets in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Terbinafine · 8.2

  “Risk Summary After oral administration, terbinafine is present in human milk.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Terbinafine · 8.4

  “The safety and efficacy of terbinafine tablets have not been established in pediatric patients with onychomycosis.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Terbinafine · 8.5

  “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.